Available now: 2020 reporting of serious adverse reactions and events for blood and blood components

The European Commission ‘Summary of the 2020 annual reporting of serious adverse reactions and events for blood and blood components’ is now available. Main findings include that only 21 out of 27 member states receive complete data from their establishments; 22.8 million units of blood or blood components were reported across countries; 1 674 serious adverse reactions, 2 604 serious adverse events and 26 deaths were reported. The full report is available here.

Stay up to date

    © CSL 2026

    Blood & Beyond is a multi-stakeholder initiative funded by CSL, involving experts from the fields of haematology, transfusion medicine, anaesthesiology, patient blood management, nursing, patient advocacy, health economics, and hospital management, with support from policymakers committed to driving improvements in this area. The aim of the initiative is to raise awareness of the importance of good blood health and of the impact of anaemia on patients, healthcare systems and society at large, with the overarching goal to help advance policies and practices that improve patient outcomes by supporting patient-centricity in anaemia prevention, diagnosis, and management through patient blood management (PBM) and innovation.

    Contact

    For further information and queries, please contact the Blood and Beyond Secretariat: javier.lopezpanos@dgagroup.com

    Privacy Preference Center